Duyuru • Jul 22
Oxygenta Pharmaceutical Limited to Report Q1, 2027 Results on Jul 27, 2026 Oxygenta Pharmaceutical Limited announced that they will report Q1, 2027 results at 12:15 PM, Indian Standard Time on Jul 27, 2026 New Risk • Jun 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹406m free cash flow). Negative equity (-₹427m). Earnings have declined by 43% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.6% average weekly change). Market cap is less than US$100m (₹1.90b market cap, or US$20.2m). Reported Earnings • May 24
Full year 2026 earnings released: ₹4.75 loss per share (vs ₹2.69 loss in FY 2025) Full year 2026 results: ₹4.75 loss per share (further deteriorated from ₹2.69 loss in FY 2025). Revenue: ₹1.13b (up 3.6% from FY 2025). Net loss: ₹175.7m (loss widened 82% from FY 2025). Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 19% per year. New Risk • Feb 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹112m free cash flow). Negative equity (-₹367m). Earnings have declined by 45% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.4% average weekly change). Market cap is less than US$100m (₹1.75b market cap, or US$19.3m). Reported Earnings • Feb 05
Third quarter 2026 earnings released: ₹1.32 loss per share (vs ₹1.07 loss in 3Q 2025) Third quarter 2026 results: ₹1.32 loss per share (further deteriorated from ₹1.07 loss in 3Q 2025). Revenue: ₹339.3m (up 2.2% from 3Q 2025). Net loss: ₹48.4m (loss widened 23% from 3Q 2025). Over the last 3 years on average, earnings per share has increased by 34% per year whereas the company’s share price has increased by 32% per year. Reported Earnings • Nov 08
Second quarter 2026 earnings released: ₹1.33 loss per share (vs ₹0.81 loss in 2Q 2025) Second quarter 2026 results: ₹1.33 loss per share (further deteriorated from ₹0.81 loss in 2Q 2025). Revenue: ₹142.5m (up 1.7% from 2Q 2025). Net loss: ₹49.3m (loss widened 73% from 2Q 2025). Over the last 3 years on average, earnings per share has increased by 38% per year whereas the company’s share price has increased by 35% per year. Duyuru • Aug 26
Oxygenta Pharmaceutical Limited Announces Change in Composition of Committees, Effective August 25, 2025 Oxygenta Pharmaceutical Limited at its board meeting held on August 25, 2025 approved change in composition of committees of board effective August 25, 2025. Audit Committee,composed of Sidda Reddy Kanuparthi as Chairman, who is an Additional Director (Independent); Sharvari Swapnil Shinde as Member, also an Additional Director (Independent); Veera Reddy Arava as Member, an Additional Director (Independent); and Chandra Mouliswar Reddy as Member, who is an Additional Director (Executive). In the Nomination and Remuneration Committee, the composition includes Veera Reddy Arava as Chairman, an Additional Director (Independent); Sidda Reddy Kanuparthi as Member, an Additional Director (Independent); and Sharvari Swapnil Shinde as Member, who is an Additional Director (Independent). Reported Earnings • Aug 16
First quarter 2026 earnings released: ₹1.65 loss per share (vs ₹0.39 loss in 1Q 2025) First quarter 2026 results: ₹1.65 loss per share (further deteriorated from ₹0.39 loss in 1Q 2025). Revenue: ₹151.3m (up 20% from 1Q 2025). Net loss: ₹61.1m (loss widened 348% from 1Q 2025). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has increased by 52% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Aug 12
Oxygenta Pharmaceutical Limited to Report Q1, 2026 Results on Aug 14, 2025 Oxygenta Pharmaceutical Limited announced that they will report Q1, 2026 results on Aug 14, 2025 New Risk • Jul 17
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹88m free cash flow). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Negative equity (-₹256m). Earnings have declined by 26% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹4.14b market cap, or US$48.2m). New Risk • Jun 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹88m free cash flow). Negative equity (-₹256m). Earnings have declined by 26% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₹4.60b market cap, or US$53.7m). Reported Earnings • Jun 02
Full year 2025 earnings released: ₹2.86 loss per share (vs ₹1.09 loss in FY 2024) Full year 2025 results: ₹2.86 loss per share (further deteriorated from ₹1.09 loss in FY 2024). Revenue: ₹1.11b (up 179% from FY 2024). Net loss: ₹103.0m (loss widened 196% from FY 2024). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • May 26
Oxygenta Pharmaceutical Limited to Report Q4, 2025 Results on May 30, 2025 Oxygenta Pharmaceutical Limited announced that they will report Q4, 2025 results on May 30, 2025 Reported Earnings • Feb 16
Third quarter 2025 earnings released: ₹1.07 loss per share (vs ₹0.99 loss in 3Q 2024) Third quarter 2025 results: ₹1.07 loss per share (further deteriorated from ₹0.99 loss in 3Q 2024). Revenue: ₹336.9m (up 268% from 3Q 2024). Net loss: ₹39.3m (loss widened 17% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has increased by 53% per year, which means it is tracking significantly ahead of earnings growth. Duyuru • Feb 08
Oxygenta Pharmaceutical Limited to Report Q3, 2025 Results on Feb 14, 2025 Oxygenta Pharmaceutical Limited announced that they will report Q3, 2025 results on Feb 14, 2025 Reported Earnings • Nov 18
Second quarter 2025 earnings released: EPS: ₹0.81 (vs ₹0.87 loss in 2Q 2024) Second quarter 2025 results: EPS: ₹0.81 (up from ₹0.87 loss in 2Q 2024). Revenue: ₹147.5m (up 13% from 2Q 2024). Net loss: ₹28.5m (loss narrowed 9.7% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 45% per year, which means it is well ahead of earnings. Duyuru • Nov 09
Oxygenta Pharmaceutical Limited to Report Q2, 2025 Results on Nov 14, 2024 Oxygenta Pharmaceutical Limited announced that they will report Q2, 2025 results on Nov 14, 2024 Duyuru • Sep 12
Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2024 Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 30, 2024, at 15:00 Indian Standard Time. Location: survey no. 252/1,aroor village, sadasivapet mandal, sangareddy district, telangana - 502291, sangareddy India Reported Earnings • Aug 16
First quarter 2025 earnings released: ₹0.39 loss per share (vs ₹1.65 loss in 1Q 2024) First quarter 2025 results: ₹0.39 loss per share (improved from ₹1.65 loss in 1Q 2024). Revenue: ₹126.4m (up 84% from 1Q 2024). Net loss: ₹13.6m (loss narrowed 70% from 1Q 2024). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 9% per year, which means it is well ahead of earnings. Duyuru • Aug 09
Oxygenta Pharmaceutical Limited to Report Q1, 2025 Results on Aug 14, 2024 Oxygenta Pharmaceutical Limited announced that they will report Q1, 2025 results on Aug 14, 2024 Duyuru • May 25
Oxygenta Pharmaceutical Limited to Report Q4, 2024 Results on May 30, 2024 Oxygenta Pharmaceutical Limited announced that they will report Q4, 2024 results on May 30, 2024 New Risk • May 23
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Negative equity (-₹244m). Earnings have declined by 29% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (6.0% increase in shares outstanding). Revenue is less than US$5m (₹373m revenue, or US$4.5m). Market cap is less than US$100m (₹1.30b market cap, or US$15.6m). Duyuru • May 23
Oxygenta Pharmaceutical Limited announced that it has received INR 32 million in funding from Amigos Molecular Solutions Private Limited On May 21, 2024, Oxygenta Pharmaceutical Limited closed the transaction. The company issued 1,700,000 shares to M V S Prasad Reddy, 200,000 shares to Amigos Molecular Solutions Private Limited and 100,000 to Rachamallu Aparna. Duyuru • Apr 09
Oxygenta Pharmaceutical Limited announced that it expects to receive INR 32 million in funding Oxygenta Pharmaceutical Limited announced a private placement to issue 2,000,000 common shares at an issue price of INR 16 per share for the gross proceeds of INR 32,000,000 on April 8, 2024. The transaction will include participation from individual investors M VS Prasad Reddy for 200,000 shares, Rachamallu Aparna for 100,000 shares and Amigos Molecular Solutions Private Limited for 200,000 shares. The transaction has been approved by the shareholders of the company and is subject general shareholders which is to be scheduled on May 09, 2024. Reported Earnings • Nov 18
Second quarter 2024 earnings released: ₹0.87 loss per share (vs ₹1.64 loss in 2Q 2023) Second quarter 2024 results: ₹0.87 loss per share. Revenue: ₹130.8m (up 116% from 2Q 2023). Net loss: ₹31.6m (loss widened 35% from 2Q 2023). New Risk • Oct 21
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 7.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹113m free cash flow). Negative equity (-₹462m). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.3% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Market cap is less than US$100m (₹1.02b market cap, or US$12.3m). Duyuru • Oct 12
Oxygenta Pharmaceutical Limited Appoints Miss. Dolly Mandhan as the Company Secretary of the Company Designated as the Key Managerial Personnel and Compliance Officer Oxygenta Pharmaceutical Limited at its board meeting held on October 11, 2023, based on the recommendation of Nomination and Remuneration Committee, approved the appointment of Miss. Dolly Mandhan as the Company Secretary of the Company (Membership No. A66040) designated as the Key Managerial Personnel pursuant to the provisions of section 203 of the Companies Act, 2013 and Compliance Officer under Regulation 6(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with effect from 01st October 2023. Appointment to fill up vacancy due to resignation of Company Secretary. Miss. Dolly Mandhan is an Associate member of the Institute of Company Secretaries of India and a Commerce Graduate from North Maharashtra University. She has over 3 years of experience in dealing in secretarial functions and compliance matters. New Risk • Aug 18
New major risk - Revenue and earnings growth Earnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹151m free cash flow). Negative equity (-₹462m). Earnings have declined by 13% per year over the past 5 years. Shareholders have been substantially diluted in the past year (136% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (7.9% average weekly change). Revenue is less than US$5m (₹290m revenue, or US$3.5m). Market cap is less than US$100m (₹1.15b market cap, or US$13.8m). Reported Earnings • Aug 18
First quarter 2024 earnings released: ₹1.65 loss per share (vs ₹1.19 loss in 1Q 2023) First quarter 2024 results: ₹1.65 loss per share (further deteriorated from ₹1.19 loss in 1Q 2023). Revenue: ₹68.6m (down 23% from 1Q 2023). Net loss: ₹45.6m (loss widened 169% from 1Q 2023). Duyuru • Jul 03
Oxygenta Pharmaceutical Limited Announces Resignation of Veerendra Babu Rangisetti as Company Secretary and Compliance Officer Oxygenta Pharmaceutical Limited announced that Mr. Veerendra Babu Rangisetti has resigned from the post of company secretary with effect from close of working hours of June 30, 2023. Consequent to his resignation as Company secretary, Mr. Veerendra Babu Rangisetti also ceases to be compliance officer of the Company. Reported Earnings • Jun 04
Full year 2023 earnings released: ₹6.36 loss per share (vs ₹0.48 loss in FY 2022) Full year 2023 results: ₹6.36 loss per share (further deteriorated from ₹0.48 loss in FY 2022). Revenue: ₹310.1m (down 49% from FY 2022). Net loss: ₹115.7m (loss widened ₹109.6m from FY 2022). Duyuru • May 25
Oxygenta Pharmaceutical Limited to Report Q4, 2023 Results on May 30, 2023 Oxygenta Pharmaceutical Limited announced that they will report Q4, 2023 results on May 30, 2023 Reported Earnings • Feb 16
Third quarter 2023 earnings released: ₹2.29 loss per share (vs ₹0.15 profit in 3Q 2022) Third quarter 2023 results: ₹2.29 loss per share (down from ₹0.15 profit in 3Q 2022). Revenue: ₹78.7m (down 51% from 3Q 2022). Net loss: ₹32.5m (down ₹34.7m from profit in 3Q 2022). Reported Earnings • Nov 16
Second quarter 2023 earnings released: ₹1.64 loss per share (vs ₹0.27 loss in 2Q 2022) Second quarter 2023 results: ₹1.64 loss per share (further deteriorated from ₹0.27 loss in 2Q 2022). Revenue: ₹60.6m (down 61% from 2Q 2022). Net loss: ₹23.4m (loss widened ₹19.5m from 2Q 2022). Duyuru • Nov 05
Oxygenta Pharmaceutical Limited to Report Q2, 2023 Results on Nov 12, 2022 Oxygenta Pharmaceutical Limited announced that they will report Q2, 2023 results on Nov 12, 2022 Duyuru • Sep 06
Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 26, 2022 Oxygenta Pharmaceutical Limited, Annual General Meeting, Sep 26, 2022, at 15:00 Indian Standard Time. Agenda: To consider and adopt the Audited Financial Statements of the Company for the year ended March 31, 2022, together with the reports of the Board of Directors and Auditors thereon; to appoint a director in place of Sri. Raghavendra Rao Kanuganti, who retires by rotation and being eligible, seeks re-appointment; To consider Re-Appointment of Dr. Sai Sudhakar Vankineni as Managing Director of the Company; and to consider other matters. Duyuru • Aug 07
Oxygenta Pharmaceutical Limited to Report Q1, 2023 Results on Aug 12, 2022 Oxygenta Pharmaceutical Limited announced that they will report Q1, 2023 results on Aug 12, 2022 Valuation Update With 7 Day Price Move • May 18
Investor sentiment improved over the past week After last week's 18% share price gain to ₹25.90, the stock trades at a trailing P/E ratio of 33.1x. Average trailing P/E is 21x in the Pharmaceuticals industry in India. Total returns to shareholders of 221% over the past three years. Reported Earnings • Feb 16
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.15 (down from ₹2.85 in 3Q 2021). Revenue: ₹159.3m (down 45% from 3Q 2021). Net income: ₹2.18m (down 93% from 3Q 2021). Profit margin: 1.4% (down from 10.0% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 79% per year but the company’s share price has only increased by 33% per year, which means it is significantly lagging earnings growth. Duyuru • Feb 09
S.S. Organics Limited to Report Q3, 2022 Results on Feb 14, 2022 S.S. Organics Limited announced that they will report Q3, 2022 results on Feb 14, 2022 Valuation Update With 7 Day Price Move • Nov 26
Investor sentiment improved over the past week After last week's 16% share price gain to ₹30.35, the stock trades at a trailing P/E ratio of 11.4x. Average trailing P/E is 22x in the Pharmaceuticals industry in India. Total returns to shareholders of 237% over the past three years. Reported Earnings • Nov 21
Second quarter 2022 earnings released: ₹0.27 loss per share (vs ₹0.67 loss in 2Q 2021) The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2022 results: Revenue: ₹154.9m (up 85% from 2Q 2021). Net loss: ₹3.88m (loss narrowed 43% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 68% per year but the company’s share price has only increased by 43% per year, which means it is significantly lagging earnings growth. Duyuru • Aug 13
S.S. Organics Limited announced that it has received INR 40 million in funding On August 12, 2021, S.S. Organics Limited closed the transaction. The company issued 4,000,000 shares at issue price of INR 10 per share for gross proceeds of INR 40,000,000. The paid up share capital of the company will be increased to INR 140,213,000 post closing of the transaction. Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment improved over the past week After last week's 21% share price gain to ₹12.19, the stock trades at a trailing P/E ratio of 4.2x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 74% over the past three years. 
